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Iranian J Parasitol: Vol.  5 , No. 2 , 20 10 , pp . 1 - 9       1                                                        Original  Article     Recombinant SAG1 Antigen to Detect  Toxoplasma gondii  Specific  Im munoglobulin G in Human Sera by ELISA Test     N Jalallou  1 , M Bandepour  2 , H Khazan  1 , A Haghighi  1 , SH Abdollahi  3 ,    *B Kazem i  1,2   1   Dept. of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University,   M.C.,  Tehran, Iran   2   Cellular and Molecular Biology Research Centers, Shahid Beheshti University,  M.C.,  Tehran, Iran   3   Dept. of Medical Microbiology,   School  of Medicine, Rafsanjan University, Rafsanjan, Iran     (Received  21 Dec  2009 ; accepted  8 May 2010 ) ’   Abstract   Background:  Although some serological tests for the detection of  Toxoplasma gondii - specific  immunoglobulin are commercially available, better diagnos tic tools are needed. The aim of pre - sent study was to evaluate the usefulness of the recombinant  Toxoplasma gondii  SAG1 antigen  for the recognition of toxoplasmosis by ELISA.    Methods:  This study was  conducted in Cellular and Molecular Biology Research Ce nters, Sha - hid Beheshti University, M.C., Tehran, Iran  in 2008 - 2009. Surface antigen 1 (SAG1), a tachy - zoite stage - specific protein, was subcloned into an expression vector and was subsequently trans - formed  into  BL21  (DE3)  pLysS  competent  bacterial  cells.  After  inducing  expression  of  the  recombi nant antigen, the protein product was purified using Ni - affinity chromatography. The  immuno reactivity of recombinant SAG1 (rSAG1) was analyzed by SDS - PAGE and western blot - ting. The reactivity of the rec - SAG1 prote in was evaluated using an ELISA.    Result:  Sensitivity and specificity of the generated recombinant - ELISA (rec - ELISA) compared  to a commercially available ELISA (com - ELISA) were 88.4% and 88%, respectively.   Conclusion:  Recombinant SAG1 produced in  E. coli  i s a promising antigen that can be used in  diag nostic assays for the detection of specific antibodies against  T. gondii .   Keywords:  Toxoplasma gondii ,   Recombinant SAG1 ,  ELISA        Corresponding Author:  Fax: +98 21 22439956,     Email :  kazemi@sbmu.ac.ir           Iranian J Parasi tol     Open access Journal at   http:// ijpa.tums.ac.ir         Tehran University of Medical  Sciences Publ i cation   http:// tums.ac.ir     Iranian Society of  Par a sitology   http:// isp.tums.ac.ir  Jalallou  et al.  Recombinant SAG1 Antigen to Detect Toxoplasma …   2   Intro duction     oxoplasmosis  is  caused  by  an  obli - gate  intra cellular  protozoan  parasite,  Toxoplasma gondii , which is able to  infect most mam mals and birds  (1) . It is esti - mated that toxoplasmosis exists in a chronic  a sympto matic form in 500 million to 1 bil - lion  people  (2) .  In  humans,  Toxoplasma  gondii   is  gener ally  asymptomatic  but  in  preg nant  women  can  result  in  congenital  infec tion with severe sequelae or late onset  eye  disease.  T.  gondii   is  also  a  frequent  cause  of  encephalitis  in  severely  immuno - sup pressed  patients  with  AIDS  (3,  4) .  Additionally,  toxoplasmosis  is  a  serious  complication following organ trans plantation  (5) .   Diagnosis  of  T.  gondii   infection   can  be  estab lished in fetus and new - born infants by  the isolation of  T. gondii  from blood or body  fluids,  by  demonstration  of  the  parasite  in  tissue, and by detection of specific nucleic  acid  sequences  with  DNA  probes  (6) .  Labora tory  diagnosis  of  Toxoplasma  infec - tion is usually based on the detection of spe - cific a ntibodies. The specificity and sensitiv - ity of these methods depend primarily on the  diagnostic  antigens  (7) .  Many  serological  tests used in the detection of  T. gondii - spe - cific  immunoglobulin  are  commercially  avail able, the majority of which use native  parasite antigens prepared from tachyzoites   grown in mice and/or  in vitro  tissue culture  that  contain  various  non - parasitic  materials  from  the  culture  media  and  the  eukaryotic  host cells  (8 - 10) . The enzyme - linked immu - nosorbent assay (ELISA) is one of the ea si - est  tests  to  perform.  Due  to  the  lack  of  a  puri fied  standardized  antigen  or a  standard  method  for  preparing  the  antigen,  it is not  surprising  that  some  interassay  variability  exists  (9) .     The major advantages of using recombinant  antigens in the diagnosis of  T. gondii  infec - tions are as foll ows: (a) the antigen composi - tion of the test is precisely known, (b) more  than one defined antigen can be used, and (c)  the  method  can  be  easily  standardized.  There fore, the use of recombinant antigens  would  allow  better  standardization  of  the  tests and  would reduce the costs of produc - tion.  These  considerations  are  very  impor - tant when, as often happens, only one serum  sample is available for testing  (11) .   To develop a standardized antigen, recombi - nant SAG1 (previously named p30) was pro - duced  in  bacterial  cells  and  purified.  This  antigen  is  one  of  the  principle  proteins  in  tachyzoites, and because of its immunologi - cal structure, SAG1 i s considered an impor - tant candidate for the development of effec - tive diagnostic reagents or subunit vaccines  that  induce  an  immunodominant  response  (12) . This antigen is suitable for  use in diag - nostic systems for detecting anti - SAG1 - spe - cific IgG and IgM antibodies. The recombi - nant SAG1 has no cross - reactivity with pro - teins from other microorganisms  (13) .   The aim of present study was to evaluate the  usefulness  of   the  recombinant   T.  gondii   SAG1  antigen  for  the  recognition  of  toxoplas mosis by ELISA.                                  Materials and Methods     Subcloning   SAG1  antigen  (accession  number   EF140712 ) was cloned into the pQE30 vec - tor  (14)  and then subcloned into the pET32a  (code: PEC 018, NRGB) expression vector.  The sequence of the insert was confirmed by  PCR   (pET32a  primers:  F  5` -   AGG  GGT  TAT GCT AGT TAT TG  - 3` and R 5` -  CTG  CTA AAT TCG AAC GCC A  - 3'; Tox P30  primers:  F  5' -   GGT  ACC  ATG  TTT  CCG  AAG GCA GTG  - 3` and R 5` -  AAG CTT  CGC ACA CAA GCT GCG AT  -  3`)  and by  T  Iranian J Parasitol: Vol.  5 , No. 2 , 20 10 , pp . 1 - 9       3   restriction  analysis  using  Pst1  (Fermentas,  Lit huania Cat).     Gene expression    The  recombinant  plasmid  was  transformed  into  Escherichia  coli   BL21  (DE3)  pLysS  competent cells. A single colony was grown  in  LB  medium  (Merck   Frankfurte ,    Ger - many,)  containing  100  µg/ml  ampicillin  over night at 37°C and then  diluted 10 - fold  with  fresh  LB  medium  contain  ampicillin.  The plasmid promoter was induced with iso - propyl - D - thiogalactopyranoside (IPTG) at a  final concentration of 1 mM. The cells were  incubated with vigorous shaking at 37°C for  7 h. The cells were harve sted by centrifuga - tion (10,000 rpm for 10 min). The expressed  protein  was  confirmed  by  SDS - PAGE  and  western blot analysis.      Protein purification    Purification was performed using Ni - affinity  chromatography (Novagen,  Madison,  USA)  according  to  the  manufac turer's  protocol  with some modification. The cell pellet (ex - tracted  from  25  ml  of  LB  medium)  was  resus pended in 4 ml of equilibration buffer  (500  mM  NaCl,  50  mM  Tris - HCl,  0.5  M  Urea) plus 1 mM PMSF ( phenylmethanesul - fonyl  fluoride )  and  incubated  overnigh t  at  4°C. The suspension was then sonicated and  centrifuged (10,000 rpm for 20 min at 4°C).  The  supernatant  was  collected  and  trans - ferred to a Ni - NTA column containing 2 ml  equilibrated  resin.  The  column  was  incu - bated overnight at 4°C and was washed with   10 ml washing buffer (1 M NaCl, 50 mM  Tris - HCl, 0.4 M urea). The bound recombi - nant  protein  was  eluted  with  2  ml  elution  buffer (500 mM NaCl, 50 mM Tris - HCl, 1  M imidazole, 0.4 M urea). The eluted frac - tion  was  dialyzed  against  PBS  buffer  (10  mM Na 2 HPO 4 ,  150 mM NaCl) and the pro - tein concentration was measured by BioPho - tometer (Eppendorf, Hamburg, Germany).     Western blot analysis    The immunoreactivity of recombinant His 6 - SAG1  was  analyzed  by  SDS - PAGE  with  Coomassie  brilliant  blue  (G  250)  staining.  The pro tein was subsequently transferred to  a nitrocellulose membrane (Porablot,  Düren ,  Germany) using a semi - dry blotting appara - tus (Apelex, France). Human serum samples  containing  T. gondii - specific IgG antibodies  or a His - tagged monoclonal antibody diluted  in   blocking  solution  (1:500  and  1:1000,  respec tively) were used as the primary anti - bodies.  Rabbit  anti - human  IgG  and  goat  anti - mouse IgG, diluted 1:000 and 1:5000 in  blocking solution, respectively, were used as  the  secondary  antibodies.  The  membrane - bound  rSAG1 was detected with DAB (3, 3' - diaminobenzidine;  Sigma,  Munich,   Ger - many).     ELISA      Each well of flat - bottomed polystyrene mi - croplates (Greiner Bio One,  Frickenhausen,   Germany) was coated  with 100 µl purified  recombinant protein at a concentration o f 4  µg/ml  in  50  mM  carbonate - bicarbonate  buffer (pH 9.6) overnight at 4°C. Wells were  washed  three  times  (PBS,  pH  7.2,  0.05%  Tween  20)  and  incubated  with  blocking  solu tion (1% BSA and 0.05% Tween 20 in  PBS)  at  room  temperature  for  2  h.  After  blocking,  100   µl  of  human  sera,  diluted  1:100 in blocking solution, was loaded into  each well and incubated for 1.5 h at room  temperature on an orbital shaker. After an - other round of washing, each well was incu - bated with 100 µl of polyclonal rabbit anti - human  IgG  hor seradish  peroxidase - conju - gated secondary antibody (Dako Cytomation,  Produktionsvej ,  Denmark)  diluted  1:10,000  in blocking solution for 1 hour at room tem - perature  on  an  orbital  shaker  and  then  washed  as  in  the  previous  step.  The  OPD  (Dako,  Produktionsvej ,   Denmark)  substrate  (100 µl; 8 mg of OPD was dissolved in 12  ml of distilled water and 4 µl H 2 O 2  prior to Jalallou  et al.  Recombinant SAG1 Antigen to Detect Toxoplasma …   4   use) was added. After 10 - min incubation at  room temperature in the dark, 50 µl of 2 N  sulfuric acid was used to stop the reaction.  The  absorbance  at  4 92  nm  was  measured  using an automated microplate reader (Sun - rise - Tecan,  Männedorf,  Switzerland ).  The  cut - off  value  was  calculated  as  the  mean  level  of  negative  sera  plus  two  standard  devia tions.   A total of 173 sample sera (153 sample sera  from patients w ith suspected  T. gondii  infec - tion and 20 sera from patients with other dis - eases)  were  tested  using  a  commercial  ELISA kit (Euroimmun,  Lübeck , Germany)  prior to testing them using our ELISA. Us - ing  the  results  of  com - ELISA,  sera  were  classi fied  as  negati ve  or  positive  for  T.  gondii .      Results     The SAG1 gene was subcloned into pET32a  and the resulting recombinant plasmid was  confirmed by PCR and sequencing methods  (Fig. 1a, b and c).   The Kpn1 and Sal1 restriction sites used for  the  ligation  of  SAG1  were  13 2  and  186  bases  downstream  of  thioredoxin,  which  con sists  of  327  nucleotides.  T he  resulting  SAG1 - thioredoxin fusion product had a mo - lecular weight that was about 16 kDa higher  than native SAG1.    The concentration of the purified protein that  was measured  by the BioPhotometer was 5  mg/ml.   Before and after purification, a pro - tein  band  was  observed  at  52.4  kDa  on  a  15% SDS - PAGE gel (Fig. 2). This band was  absent  in  uninduced cultures  and  in an  in - duced  control  culture  of  cells  lacking  the  SAG1 insert.   The i mmunoreactivity of the antigen before  and  after  purification  was  confirmed  by  west ern  blot  analysis  using  a  monoclonal  antibody  against  His - tag  in  addition  to  the  human  serum  samples,  which  were  previ - ously  characterized  for  T.  gondii   specific  IgG reactiv ity (Fig. 3).   The rSAG1 protein expressed in  E. coli  was  evaluated  by  ELISA  to  assess  whether  it  would be a useful antigen for serodiagnosis  of toxoplasmosis. One hundred and seventy - three serum samples were tested by both the  com - ELISA kit and the rec - ELI SA. Twenty  serum  samples  had  IgG  antibodies  against  other diseases (Table 1), although they ap - peared to be negative for  T. gondii .   The cut - off value was set equal to the average OD  value  of  the  negative  population  plus  two  standard deviations (Fig. 4).   Th e result of the commercial and recombi - nant  ELISAs  are  summarized  in  Table  2.   The sensitivity and specificity of our assay  using  T. gondii  recombinant protein antigens  with respect to the com - ELISA were 88.4%  and 88%, respectively.       Table 1:  Diseases tes ted for cross - reactivity to rSAG1     Diseases   EBV   VZV   HSV   Rub   Measles   M.t.   H.p.   CMV   Number   4   2   2   2   2   3   3   2     EBV: Epstein - Barr virus; VZV: Varicella zoster virus; HSV: herpes - simplex virus; Rub: rubella;  M.t:  Mycobacterium tuberculosis ; H.p:  Helicobacter py lori ; CMV: Cytomegalovirus      Iranian J Parasitol: Vol.  5 , No. 2 , 20 10 , pp . 1 - 9       5   Table 2:  Comparison of com - ELISA and rec - ELISA         com - ELISA         Total   Negative   Positive       84   8   76   Positive     69   59   10   Negative   rec - ELISA - 153   67   86   Total           Fig. 1:  Confirmation of subcloning. A PCR was performed using pET3 2a (panel a) and ToxoP30 primers  (panel b). The resulting amplicon was separated by electrophoresis on a 1.5% agarose gel. The reaction of  confirmation enzyme is shown in panel c. Panel a: lanes 1 - 2, pET32a without the SAG1 insert (200 bp);  lanes 3 - 4, pET3 2a containing the SAG1 insert (1157 bp); lane 5, DNA ladder. Panel b: lane 1, SAG1 gene  (957 bp); lane 2, DNA ladder. Panel c: lane 1, uncut recombinant pET32a; lane 2, Pst1 - digested recombi - nant pET32a (1237 bp); lane 3, DNA ladder; lane 4, uncut pET32a,  Pst1 digested pET32a (without the  1237 - bp band)       Fig.  2:  SDS - PAGE analysis of rSAG1 expression using 15% SDS - PAGE. Lane 1, molecular protein  marker (Fermentas, Lithuania Cat). Lane 2, purified rSAG1 protein. Lane 3, blank. Lane 4, expression of  SAG1 fusi on protein at 52.4 kDa after 7 h of induction. Lane 5, induced control culture of cells lacking  the SAG1 insert  Jalallou  et al.  Recombinant SAG1 Antigen to Detect Toxoplasma …   6       Fig. 3:  Western blot analysis of the rSAG1 protein using a monoclonal antibody targeting the His - tag.  Lane 1, induced control culture of cell s lacking the SAG1 insert Lane 2, expression of the SAG1 fusion  protein at 52.4 kDa. Lane 3, purified rSAG1 protein. Lane 4, molecular protein marker         Fig. 4:  Profile of the antibody response in the rec - ELISA of human sera using the rSAG1 protein (cut - o ff  value: 0.477)     Discussion     There  have  been  several  reports  regarding  the expression and purification of  T. gondii   antigens  using  various  expression  systems  including  E. coli , a mammalian cell expres - sion system, or  Pichia pastoris   (15 - 18) . Here  we subcloned the DNA sequence of the  T.  gondii   SAG1  protein  into  the  pET32a  T7  promoter - based  expression  vector.  In  this  vector,  the  insert  is  expressed  as  a  fusion  pro tein with  E. coli  thioredoxin (trxA). This  protein  ha s  been  stably  expressed  at  high  levels  in  the  pET  system and is extremely  soluble  in  the  E.  coli   cytoplasm  (19) .  In  addi tion to its solubility, trxA is small (109  aa; 11,675 kDa), has inherent thermal  stabil - ity, is localized on the cytoplasmic face of  the  adhesion  zones  between  the  inner  and  oute r cell membranes and can be exploited  for  rapid  purification  (20) .  The  rec - protein  was  purified  using  a  simple  purification Iranian J Parasitol: Vol.  5 , No. 2 , 20 10 , pp . 1 - 9       7   method  according  to  the  manufacturer's  proto col with some modification. The iden - tity  rec - protein  was  confirmed  by  western  blotting, which showed the immunoreactiv - ity of the spec ific protein. Thus, we success - fully  produced  large  quantities  of  highly  puri fied protein in our laboratory.   Routine diagnosis of  T. gondii  infection re - lies primarily on serological recognition. A  precise  distinction  between  the  acute  and  latent forms ma y be difficult since IgM anti - bodies, which are considered to be specific  markers of early infection, may be present in  sera for many years ( 21) . An alternate, more  reliable diagnostic test is needed.    Here,  we  evaluated  the  development  of  an  ELISA  technique  using  rSAG1  and  its  useful ness for serodiagnosis of toxoplasmo - sis in humans.   A robust i mmunological response to the sur - face  antigen  SAG1  is  associated  with  chronic  Toxoplasma   invasion  (22) .  In  our  study, rSAG1 was recognized in more than  88% of positive sera from IgM - negative pa - tients.   Buffolano et  al. (23) previously reported that  SAG1  reacted  with  75%  of  the  sera  from  con genitally  infected  infants.  In  a  survey  pub lished by Aubert et al. (9), rSAG1 rec - ELISA could recognize 83% of IgG antibod - ies against toxoplasmosis in chronically in - fected indi viduals, which is consistent with  our results.   Pietkiewiez  et  al.  used  sera  from  patients  with  indicative  infections  acquired  in  the  dis tant  past  (chronic  toxoplasmosis)  and  showed that increasing the level of antibody  titers  increased  the  ability  of  rSAG 1  to  recog nize positive sera (from 70% to 100%)  (24).  These results  are  within  the  range  of  our findings.   In  agreement  with  the  results  obtained  by  Velmurugan  et  al.  (25),  the  specificity  and  sen sitivity of rSAG1 were 88.4% and 83.3%  in goat sera, respec tively. These percentages  are very similar to our data.   In contrast, Nigro et al. (26) showed low or  no  reactivity  against  rSAG1.  It  is  possible  that  they  used  a  truncated  gene  and  a  purifica tion method that resulted in incorrect  folding of the recombinan t protein.    We did not observe any cross - reactivity with  other  vertically  transmittable  diseases  (Cy - tomegalovirus,  Herpes  simplex  virus,  Ru - bella, Varicella zoster virus), mycobacterium  tuberculosis,  Helicobacter  pylori,  Epstein  bar virus, or measles usin g the rSAG1 pro - tein. This finding verifies results of Harning  et al. (13).   In conclusion, recombinant SAG1 pro duced  in  E. coli  is a promising antigen that can be  used in diagnostic assays for the detec tion of  specific antibodies against  T. gondii . Assay s  based on recombinant pro teins are easier to  standardize  and  are  more  reproducible  be - cause only a single protein with a few immu - nodominant epitopes is used  (13) .     Acknowledgements     The authors would like to thank L. Maghen  and all ma nagers and staff of the Department  of  Medical  Parasitology  and  Mycology.  Addi tionally,  we  express  appreciation  to  Sha hid  Beheshti  University  for  their  pre - cious  collaboration.  This  work  was  finan - cially supported by Cellular and Molecular  Biology Researc h Centers, Shahid Beheshti  University, M.C., Tehran, Iran. The authors  declare that they have no conflicts of interest.        References     1 .   Wong SY, Remington JS. Biology of  Toxoplasma  gondii .  AIDS.  1993;  7:299 – 316.   2 .   Tenter AM, Heckeroth AR, Weiss LM.  Toxoplasma   gondii :  from  ani mals  to  hu mans. Int J Parasitol. 2000; 30:1217 – 58.  Jalallou  et al.  Recombinant SAG1 Antigen to Detect Toxoplasma …   8   3 .   Araujo  FG,  Remington  JS.  Toxoplas - mo sis in immunocompromised pa tients.  Eur J Clin Microbiol. 1987; 6:1 – 2.   4 .   Pinon JM, Chemla C, Villena I, Foudrinier  F, Aubert D, Puygauthier - Tou bas D,  et al .  Early  neonatal  diagno sis  of  congenital  toxoplasmo sis: value of comparative en - zyme - linked  immuno filtration  assay  immu nological  profiles  and  anti - Toxoplasma  gondii   im munoglobulin  M  (IgM)  or  IgA  immu nocapture  and  implica tions  for  post natal  the rapeutic  strate gies.  J  Clin  Mi crobiol.    1996;  34:579 – 583.   5 .   Aubert D, Foudrinier F, Villena I, Pi - non JM, Biava MF, Renoult E. PCR for  diagnosis and follow - up of two cases of  disseminated  toxoplasmosis  after  kid - ney grafting. J Clin Micro biol.  1996;  34:1 347.   6 .   Remington JS, McLeod R, Desmonts G.  Toxoplasmosis.  In:  Remigton  JS  and  Klein JO, editors. Infectious dis eases of  the  fetus  and  newborn  infant.  W.  B.  Saun ders, Philadelphia, Pa; 1995.p.140 - 267.   7 .   Joyson  DHM,  Guy  EC.  Laboratory  diagnosis of  Toxoplasma  i nfection. In:  Joynson  DHM,  Wreghitt  TG,  edi tors.  Toxoplasmosis. A comprehen sive clini - cal guide. Cambridge Univer sity Press,  Cambridge; 2001.p. 296 - 318.    8 .   Johnson  AM,  Roberts  H, Tenter  AM.  Evaluation  of  a  recombinant  antigen  ELISA  for  the  diagnosis  of  ac ute  toxoplasmosis and comparison with tra - di tional antigen ELISAs. J Med Mi cro - biol.  1992; 37:404 – 9.   9 .   Aubert D, Maine GT, Villena I, Hunt  JC, Howard L, Sheu M,  et al.   Recom - bi nant  antigens  to  detect  Toxoplasma  gondii - specific immu noglobulin G and  immu noglobulin M in human sera by  en zyme immunoas say. J Clin Microbiol.  2000; 38:1144 – 50.   10 .   Li S, Maine G, Suzuki Y, Araujo FG,  Galvan G, Remington JS,  et al . Serodi - ag nosis  of  recently  acquired  Toxoplasma gondii  infection with a re - combinant  antigen.  J  Clin  Micro biol.  2000; 38:179 – 84.   11 .   Pietkiewicz H, Hiszczynska - Sawicka E,  Kur J, Petersen E, Nielsen HV, Paul M,  et al . Usefulness of  Toxoplasma gondii  re combinant  anti gens  (GRA1,  GRA7  and  SAG1)  in  an  immunoglobulin  G  avid ity  test  for  the  serodiagnosis  of  toxo plasmosis.  Parasitol  Res.  2007;  100:333 – 7   12 .   Burg  JL,  Perelman  D,  Kasper  LH,  Ware  PL,  Boothrovd  JC.  Molecular  analy sis of the gene encoding the ma jor  surface antigen of  Toxoplasma gondii.  J  Immunol. 1988; 141:3584 – 91.   13 .   Harning D, Spenter J, Metsis A, Vuust  J ,  Petersen  E.  Recombinant  Toxoplasma  gondii  surface  antigen  1  (P30) expressed in  Escherichia coli  is  rec ognized by human  Toxoplasma - spe - cific immunoglobulin M (IgM) and IgG  antibodies.  Clin  Diagn  Lab  Immunol.  1996; 3:355 – 7.   14 .   Kazemi B, Bandehpour M, Maghen  L,  Solgi  GH.  Gene  Cloning  of  30  kDa  Toxoplasma gondii  tachyzoites sur face  antigen  (SAG1).  Iranian  J  Para sitol.  2007; 2:1 – 8.   15 .   Darcy F, Maes P, Gras - Masse H, Auri - ault  C,  Bossus  M,  Deslee  D,  et  al .  Protec tion of mice and nude rats against  toxoplasmosis by  a multiple an tigenic  peptide  construction  de rived  from  Toxoplasma  gondii  P30  an tigen.  J  Immu nol. 1992;  149:3636 – 41 .   16 .   Xiong  C,  Grieve  RB,  Kim  K,  Boothroyd  JC.  Expression  of  Toxoplasma gondii  P30 as fusions with  glutathione S - transferase in ani mal cells   by Sindbis recombinant vi rus. Mol Bio - chem Parasitol.  1993; 61:143 – 8.  Iranian J Parasitol: Vol.  5 , No. 2 , 20 10 , pp . 1 - 9       9   17 .   Chen XG, Gong Y, Hua L, Lun ZR,  Fung MC,  et al . High - level expres sion  and  purification  of  immuno genic  recombi nant  SAG1  (P30)  of  Toxoplasma gondii  in  Escherichia coli .  Protein Expr  Purif. 2001; 23:33 – 7 .   18 .   Zhou H, Gu Q, Zhao Q, Zhang J, Cong  H,  Li  Y,  et  al .  Toxoplasma  gondii :  expres sion and characteriza tion of a re - combinant  protein  contain ing  SAG1  and GRA2 in  Pichia pastoris . Parasitol  Res.  2007; 100:829 – 35.   19 .   Lunn  CA,  Kathju  S,  Wall ace  BJ,  Kushner  SR,  Pigiet  V.  Amplification  and  purification  of  plasmid - encoded  thio redoxin from  Escherichia coli  K12.  J Biol Chem. 1984; 259:10469 – 74.   20 .   Bayer ME. Areas of adhesion be tween  wall and membrane of  Es cherichia coli .  J Gen Microbiol.  1968; 53:395 – 40.   21 .   Meek B, van Gool T, Gilis H, Peek R.  Dissecting the IgM antibody re sponse  during  the  acute  and  latent  phase  of  toxoplasmosis. Diagn Micro biol Infect  Dis. 2001; 41:131 – 7.   22 .   Gatkowska J, Hiszczynska - Sawicka E,  Kur  J,  Hole c  L,  Dlugonska  H.  Toxoplasma gondii : an evaluation of di - ag nostic value of recombinant anti gens  in a murine model. Exp Parasitol. 2006;  114:220 – 7.   23 .   Buffolano W, Beghetto E, Del Pezzo M,  Spadoni A, Di Cristina M, Petersen E,  et al .  Use of recombinant antig ens for  early postnatal diagnosis of congenital  toxoplasmosis. J Clin Microbiol. 2005;   43:5916 – 24.   24 .   Pietkiewicz H, Hiszczynska - Sawicka E,  Kur  J,  Petersen  E,  Nielsen  HV,  Stankiewicz  M,  et  al .  Usefulness  of  Toxoplasma  gondii - specific  recombi - nant  antigens  in   serodiagnosis  of  hu - man toxoplasmosis.  J  Clin  Microbiol.  2004; 42:1779 – 81.   25 .   Velmurugan GV, Tewari AK, Rao JR,  Baidya  S,  Kumar  MU,  Mishra  AK.  High - level  expression  of  SAG1  and  GRA7  gene  of  Toxoplasma  gondii  (Izat nagar isolate) and their application  in sero diagnosis of goat toxoplasmosis.  Vet Parasitol. 2008; 154:185 – 92.   26 .   Nigro  M,  Gutierrez  A,  Hoffer  AM.  Evaluation  of  Toxoplasma  gondii  recom binant proteins for the diagnosis  of recently acquired toxoplasmosis by  an immunoglobulin G analysis. Diagn  Mi crobiol  Infect Dis. 2003; 47:609 – 13.            